+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Viekira"

Hepatitis C Drugs Market Global Forecast by Drugs, Distribution Channels, Regions, Company Analysis - Product Thumbnail Image

Hepatitis C Drugs Market Global Forecast by Drugs, Distribution Channels, Regions, Company Analysis

  • Report
  • May 2020
  • 194 Pages
  • Global
From
Disease Overview: Hepatitis C Disease Forecast and Market Analysis to 2035 - Product Thumbnail Image

Disease Overview: Hepatitis C Disease Forecast and Market Analysis to 2035

  • Report
  • January 2018
  • 618 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Viekira market is a subset of the larger Liver and Kidney Disorders Drugs market. It is composed of drugs used to treat chronic hepatitis C virus (HCV) infection. Viekira is a combination of two direct-acting antiviral (DAA) drugs, ombitasvir and paritaprevir, which are used in combination with ritonavir and dasabuvir. The drugs are used to treat HCV genotypes 1, 4, 5, and 6. Viekira is also used in combination with ribavirin for genotypes 2 and 3. The Viekira market is highly competitive, with several companies offering similar products. Some of the major players in the market include AbbVie, Gilead Sciences, Merck & Co., Bristol-Myers Squibb, and Janssen Pharmaceuticals. Show Less Read more